Effect of a New BI-specifiC Antibody Towards Dendritic Cells on Inflammation in Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
First, this study will evaluate, in vitro, the cellular composition of the synovial fluid from patient with rheumatoid arthritis, gout or osteoarthritis. Then samples will be test with a new format of bispecific antibody targeting dendritic cells. The production of IL-10 will be the principal criteria of judgment. Production of others cytokines like IL-1B, IL-6, IL-12 and IFN will be checked as well.

Detailed Description
-----------------
Rheumatoid arthritis (RA) is one of the most common autoimmune disease in adult. It exists several drugs but none target dendritic cells even if it seems they play a major role in the physiopathology. One of the unit of research of Tours recently develop a new format of bispecific antibody which target dendritic cells. The first results in PBMC (unpublished yet) show an increase of the production of IL-10 In this study, we are going to first evaluate the cellular composition of synovial fluid from patients with RA and patients with gout (for the comparison, because the inflammatory mechanisms are different) and with osteoarthritis (comparison with a non inflammatory disease) Then, we will use this new antibody and evaluate the response by dosing Il-10, IL-6, IL-12, IL1B and IFNy The aim is to verify in vitro if, with this new drug, it is possible to reverse the inflammation and induce a tolerance.

Official Title
-----------------
Effect of a New BI-specifiC Antibody Towards Dendritic Cells on Inflammation in Rheumatoid Arthritis

Conditions
-----------------
Rheumatoid Arthritis, Gout, Osteoarthritis

Intervention / Treatment
-----------------
* Other: Puncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female over 18 years old Proven and possible RA or Gout or osteoarthritis Arthritis accessible to a puncture Necessary puncture for diagnosis or therapeutic Exclusion Criteria: Microcrystalline rheumatism other than Gout Known SpA Septic arthritis Biomedicament treatment Patient having objected to the processing of his data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Puncture<br>Patient with RA or gout or osteoarthritis and performing a puncture. The aim is evaluate the cellular composition of synovial fluid then evaluate the response to a new BI-specifiC Antibody Towards Dendritic Cells. | Other: Puncture<br>* Puncture necessary for daily practice in patients with acute arthritis of RA or Gout or osteoarthritis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Production of IL-10 | Evaluate the production of IL-10 by cells from synovial fluid after the use of a new antibody format | 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Production of Il-6 | Evaluate the production of IL-6 by cells from synovial fluid after the use of a new antibody format | 48 hours | 
| Production of IFN | Evaluate the production of IFN by cells from synovial fluid after the use of a new antibody format | 48 hours | 
| Production of IL1B | Evaluate the production of IL1B by cells from synovial fluid after the use of a new antibody format | 48 hours | 
| Production of IL12 | Evaluate the production of IL12 by cells from synovial fluid after the use of a new antibody format | 48 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rheumatoid arthritis, Dendritics cells